InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,616.34
(
0.20%
)

Replies to post #226587 on Biotech Values

Replies to #226587 on Biotech Values

swampboots

10/31/19 12:10 PM

#226588 RE: DewDiligence #226587

You are correct, and have inflicted the type of conviction, which translates into making ISEE as worthless as GENR!

DewDiligence

11/05/19 6:00 PM

#226697 RE: DewDiligence #226587

Typo correction: BVCA—>BCVA (Best Corrected Visual Acuity).

p.s. ISEE is having its 3Q19 CC one week from today. Might be worth a listen for the entertainment value.

DewDiligence

11/12/19 11:49 AM

#226835 RE: DewDiligence #226587

ISEE succumbs to Zebra's Law:

https://www.businesswire.com/news/home/20191112005548/en

DewDiligence

11/14/19 11:30 AM

#226911 RE: DewDiligence #226587

ISEE schedules spincast on Zimura:

https://www.businesswire.com/news/home/20191114005114/en

DewDiligence

04/03/20 10:27 AM

#230405 RE: DewDiligence #226587

Sucker PR du jour:

https://www.businesswire.com/news/home/20200403005012/en

FDA Fast Track designation (as opposed to BTD) means almost nothing. Moreover, ISEE’s Zimura program in dry AMD has some serious questions (#msg-152020152).